Biofrontera (NASDAQ:BFRI) Trading Down 1.1%
Biofrontera (NASDAQ:BFRI) Trading Down 1.1%
Biofrontera Inc. (NASDAQ:BFRI – Get Rating) fell 1.1% on Monday . The stock traded as low as $0.91 and last traded at $0.93. 3,094 shares were traded during mid-day trading, a decline of 100% from the average session volume of 1,218,819 shares. The stock had previously closed at $0.94.
纳斯达克(BFRI-GET)周一下跌1.1%。该股交易价格低至0.91美元，最后报0.93美元。午盘成交量为3,094股，较1,218,819股的平均日成交量下降100%。该股此前收盘价为0.94美元。
Biofrontera Stock Performance
Biofrontera股票表现
The stock has a fifty day moving average price of $1.01 and a 200-day moving average price of $1.29. The firm has a market cap of $24.83 million, a PE ratio of -0.82 and a beta of 1.12.
该股的50日移动均价为1.01美元，200日移动均价为1.29美元。该公司市值为2483万美元，市盈率为-0.82，贝塔系数为1.12。
Biofrontera (NASDAQ:BFRI – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.09. Biofrontera had a negative net margin of 44.62% and a negative return on equity of 113.65%. The firm had revenue of $4.32 million for the quarter, compared to analysts' expectations of $4.32 million. As a group, equities analysts predict that Biofrontera Inc. will post -0.92 earnings per share for the current fiscal year.
纳斯达克(BFRI-GET Rating)上一次公布季度收益是在11月14日(星期一)。该公司公布本季度每股收益(0.23美元)，比分析师普遍预期的(0.32美元)高出0.09美元。Biofrontera的净利润率为负44.62%，净资产回报率为负113.65%。该公司当季营收为432万美元，高于分析师预期的432万美元。股票分析师预计，作为一个整体，Biofrontera Inc.本财年每股收益将达到0.92美元。
Institutional Trading of Biofrontera
生物前翅目昆虫的制度性交易
Biofrontera Company Profile
Biofrontera公司简介
(Get Rating)
(获取评级)
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
Biofrontera Inc是一家生物制药公司，在美国从事治疗皮肤病的药物产品的商业化。该公司提供处方药Ameluz和用于光动力疗法的RhodoLED灯系列，用于面部和头皮轻至中度光化性角化病的病变导向和视野导向治疗。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Biofrontera (BFRI)
- Three Healthcare Penny Stocks to Watch In The New Year
- Southwest Airlines Stock, There is a Lot to Love
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- 免费获取StockNews.com关于生物前翅目(BFRI)的研究报告
- 新年值得关注的三只医疗保健便士股
- 西南航空公司股票，有很多值得爱的东西
- MarketBeat：回顾一周12/19-12/23
- 这些钢铁制造商理应在2023年观察名单上占有一席之地
- 通胀降温，标普500指数何去何从
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Biofrontera Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Biofrontera和相关公司的最新新闻和分析师评级的每日简要摘要。